NEUWAY Pharma appoints Dr. Rudi Scherhag to the Board as CEO and Managing Director

– GERMANY, Bonn – NEUWAY Pharma announced today the appointment of Dr. Rudi Scherhag as Chief Operating Officer and Managing Director. Dr. Scherhag has extensive experience in managing various development projects from pre-clinical to registration in the pharmaceutical and biotech industry.
As planned, Dr. Scherhag will take over the managing director position from Dr. Stephan Rapp, who will focus on new projects and act as consultant and shareholder of NEUWAY.

Dr. Scherhag has made his most important professional step at Boehringer Mannheim/Roche, where he successfully managed the global development of its blockbuster product Epoetin beta. He also played a major role in the establishment of two companies. As a Member of the Executive Board at Heidelberg Pharma , Dr. Scherhag was responsible for project and business development. Before joining Neuway, he served as Managing Director at ImClone Systems International, a newly founded European clinical development organization of the US biotech company ImClone Systems Corp.

„We are glad to strengthen our team with Dr. Scherhag“, commented Dr. Heiko Manninga, Co-Founder, Chief Scientific Officer und Managing Director at NEUWAY. „With his experience he will provide significant contributions to the further development of our company. I am very much looking forward to working with him.“
Dr. Rainer Strohmenger, Chairman of NEUWAY’s advisory board and General Partner at Wellington Partners, added: „With his considerable experience and expertise in the field of drug and business development, I am convinced that Dr. Scherhag will make an important contribution to the success of NEUWAY’s innovative CNS drug delivery technology. On behalf of all shareholders, I thank Dr. Stephan Rapp for his outstanding work in developing NEUWAY. He leaves behind an excellently-positioned young biotechnology companies with exceptional potential.“NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.